Search Results
Search results for "Juan Jose Fung"
Results found for "Juan Jose Fung"
- 📰 GPCR Weekly News
team in Oxford, buying out a fledgling biotech for $255M+ Domain Therapeutics announces first patient dosed
- Four Reasons to Measure GPCR Signaling Bias in Drug Discovery
Dose-response curves for incretin agonists on GLP-1 and GIP receptors.
- Odorant receptors – a bit of smell for drug discovery
ORs are highly expressed by olfactory sensory neurons of the nose where they are activated by different analyses, have indicated that OR genes are also expressed in non-olfactory tissues including the testis, lung epithelial cells proliferation via activation by β-ionone which initiates prostate cancer cell cycle arrest (Jones In non-small-cell lung cancer OR2J3 activation induced apoptosis and inhibited cell proliferation and
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
. 👉 Biotech founders often delay critical business moves, hiring, BD outreach, or funding decisions,
- Overview of adhesion GPCRs self-activation
Qian, Y., Ma, Z., Liu, C., Li, X., Zhu, X., Wang, N., Xu, Z., Xia, R., Liang, J., Duan, Y., Yin, H.,
- 📰 GPCR Weekly News, November 6 to November 12, 2023
Months of 2023 InterAx Biotech Announces Being the Recipient of a Highly Competitive European Grant to Fund
- 📰 GPCR Weekly News, February 6 to 12, 2023
Informatics Head or Team Lead (depending on experience) with Structural Bioinformatics Expertise Fully Funded
- The One Reason Why Biotech Startups Fail More Often Than They Should
Science evolves in parallel with regulatory funding pressure and team growth.  Without it, even strong science slowly loses direction. 👉 Understanding why biotech startups fail  is
- The Real Cost of Strategic Overload in Biotech
The scientific ambition may be impressive, yet the strategic narrative loses sharpness. A startup is not a fund.
- The Moment Biotech Founders Realize the Money Is Gone
Why biotech founders lose financial control without seeing it coming, and what has to be in place early For Biotech Founders, the real danger is not running out of money, but losing financial control early This is where many biotech founders lose visibility. The moment biotech founders lose flexibility is long before the bank account becomes the problem. Decisions get postponed in the hope that the next data readout, the next partnership, or the next funding
- 📰 GPCR Weekly News, December 11 to 17, 2023
Fibrosis Former execs from Pfizer obesity drug program have started a new biotech with $52M from VC fund
- 📰 GPCR Weekly News, May 6 to 12, 2024
and Intermediate States of Orexin 2 Receptor Signaling Industry News Addex Gets Creative To Secure Funding
- Glyco-sulfo hotspots in the chemokine receptor system
sulfated mCCR2 peptides can outcompete available chemokines, decreasing retinal degradation in mice (Jung
- 📰 GPCR Weekly News, April 15 to 21, 2024
Live-cell Imaging of Bioactive Peptides Cascaded amplifying circuit enables sensitive detection of fungal
- 📰 GPCR Weekly News, May 29 to June 4, 2023
GPCRs in Oncology and Immunology A2aR on lung adenocarcinoma cells: A novel target for cancer therapy Components of TOR and MAP kinase signaling control chemotropism and pathogenicity in the fungal pathogen
- 📰 GPCR Weekly News, March 13 to 19, 2023
Signaling Components of TOR and MAP kinase signaling control chemotropism and pathogenicity in the fungal






